HA-RESEARCH.COM
J. W. Kuo, Ph.D., is an independent researcher and consultant, who has focused on
hyaluronan (HA)-related science, technology, and product development.
Dr. Kuo is the sole author of “Practical Aspects of Hyaluronan Based Medical Products”
published in 2005 by CRC Press (Taylor Francis) and the coauthor of the chapter of
“Hyaluronic Acid” in Comprehensive Biomaterials, Elsevier 2011. He had a number of
publications in peer-reviewed journals, most of which involve hyaluronan, and he has
been issued, as a co-inventor, several HA related patents by the United States Patent
and Trademark Office.
Dr. Kuo has over 30 years of industry experience in the development of HA-related
products and technology and management of its intellectual property either as full time
senior research manager of companies or as independent consultant.
(1) R&D effort in the chemistry, chemical modification, formulation, and testing of HA
based products for new applications;
(2) Manufacturing technology involving the isolation, purification, and characterization of
HA from various sources;
(3) Collaboration with academic and medical institutions in activities relating to preclinical
and clinical studies;
(4) The safety and performance assessments pertinent to such products, and the draft
of their technical reviews for submission to regulatory agencies in the U.S. and EU; and
(5) Quality assurance and quality control of HA operations in compliance with FDA Quality
System regulation and ISO standards.
For his doctoral degree, Dr. Kuo conducted HA-related research in the department of
chemistry, State University of New York at Stony Brook. He worked as director of basic
research (1989 to 1992), vice president of research and development for MedChem
Products, Woburn, Massachusetts (1992 to 1993), and served as vice president of
research and development (1993 to1995), and vice president of technical and clinical
affairs (1995 to 1998) of Anika Therapeutics also in Woburn Massachusetts. In working
with Spray Venture Capital, in Boston, he was active in the start-up of Exhale
Therapeutics, an HA company, as a consultant (1999 to 2000), and he served as its vice
president of chemistry from 2001 to 2002. From 2011 to 2013 he was again employed
by Anika Therapeutics, as Chief Scientific Officer.
hyaluronan (HA)-related science, technology, and product development.
Dr. Kuo is the sole author of “Practical Aspects of Hyaluronan Based Medical Products”
published in 2005 by CRC Press (Taylor Francis) and the coauthor of the chapter of
“Hyaluronic Acid” in Comprehensive Biomaterials, Elsevier 2011. He had a number of
publications in peer-reviewed journals, most of which involve hyaluronan, and he has
been issued, as a co-inventor, several HA related patents by the United States Patent
and Trademark Office.
Dr. Kuo has over 30 years of industry experience in the development of HA-related
products and technology and management of its intellectual property either as full time
senior research manager of companies or as independent consultant.
(1) R&D effort in the chemistry, chemical modification, formulation, and testing of HA
based products for new applications;
(2) Manufacturing technology involving the isolation, purification, and characterization of
HA from various sources;
(3) Collaboration with academic and medical institutions in activities relating to preclinical
and clinical studies;
(4) The safety and performance assessments pertinent to such products, and the draft
of their technical reviews for submission to regulatory agencies in the U.S. and EU; and
(5) Quality assurance and quality control of HA operations in compliance with FDA Quality
System regulation and ISO standards.
For his doctoral degree, Dr. Kuo conducted HA-related research in the department of
chemistry, State University of New York at Stony Brook. He worked as director of basic
research (1989 to 1992), vice president of research and development for MedChem
Products, Woburn, Massachusetts (1992 to 1993), and served as vice president of
research and development (1993 to1995), and vice president of technical and clinical
affairs (1995 to 1998) of Anika Therapeutics also in Woburn Massachusetts. In working
with Spray Venture Capital, in Boston, he was active in the start-up of Exhale
Therapeutics, an HA company, as a consultant (1999 to 2000), and he served as its vice
president of chemistry from 2001 to 2002. From 2011 to 2013 he was again employed
by Anika Therapeutics, as Chief Scientific Officer.
 |  |  |  |